Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives

References

• TaherATMusallamKMCappelliniMDWeatherallDJOptimal management of β thalassaemia intermediaBr J Haematol2011152551252321250971
   PubMed Web of Science ®Google Scholar
• TaherATViprakasitVMusallamKMCappelliniMDTreating iron overload in patients with non-transfusion-dependent thalassemiaAm J Hematol201388540941523475638
   PubMed Web of Science ®Google Scholar
• LadisVBerdousiHGotsisEKattamisADeferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermediaBr J Haematol2010151550450820950401
   PubMed Web of Science ®Google Scholar
• TonySDaarSElshinawyMAl-ZadjalySAl-KhaboriMWaliYT2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron storesPediatr Hematol Oncol201229657958422839111
   PubMed Web of Science ®Google Scholar
• ChuiDHFucharoenSChanVHemoglobin H disease: not necessarily a benign disorderBlood2003101379180012393486
   PubMed Web of Science ®Google Scholar
• MusallamKMRivellaSVichinskyERachmilewitzEANon-transfusion-dependent thalassemiasHaematologica201398683384423729725
   PubMed Web of Science ®Google Scholar
• QariMHWaliYAlbagshiMHRegional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf areaOrphanet J Rare Dis2013814324044606
   PubMed Web of Science ®Google Scholar
• Northern California Comprehensive Thalassemia CenterStandard-of-Care Clinical Practice Guidelines (2012) Available from: http://thalassemia.com/treatment-guidelines-4.aspx#gsc.tab=0Accessed June 27, 2016
   Google Scholar
• PrabhuRPrabhuVPrabhuRSIron overload in beta thalassemia: a reviewJ Biosci Tech2009112031
   Google Scholar
• WoodJCMagnetic resonance imaging measurement of iron overloadCurr Opin Hematol200714318319017414205
   PubMed Web of Science ®Google Scholar
• WoodJCDiagnosis and management of transfusion iron overload: the role of imagingAm J Hematol20078212 Suppl1132113517963249
   PubMed Web of Science ®Google Scholar
• ShethSSQUID biosusceptometry in the measurement of hepatic ironPediatr Radiol20033637337712768253
   PubMed Web of Science ®Google Scholar
• ChapmanRWWilliamsGBydderGDickRSherlockSKreelLComputed tomography for determining liver iron content in primary haemochromatosisBr Med J198028062124404427370525
   PubMed Web of Science ®Google Scholar
• BhatAAParwaniRNWanjariSPDemonstration of iron in exfoliated buccal cells of β-thalassemia major patientsJ Cytol201330316917324130408
   PubMed Web of Science ®Google Scholar
• BaconBRBrittonRSThe pathology of hepatic iron overload: a free radical-mediated processHepatology19901111271372153094
   PubMed Web of Science ®Google Scholar
• EngleMAErlandsonMSmithCHLate cardiac complications of chronic, severe, refractory anemia with hemochromatosisCirculation19643069870514226168
   PubMed Web of Science ®Google Scholar
• GrundyRGWoodsKASavageMOEvansJPRelationship of endocrinopathy to iron chelation status in young patients with thalassaemia majorArch Dis Child19947121281327944532
   PubMed Web of Science ®Google Scholar
• KwanEYLeeACLiAMA cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong KongJ Paediatr Child Health199531283877794630
   PubMed Web of Science ®Google Scholar
• De SanctisVGrowth and puberty and its management in thalassemiaHorm Res200258Suppl 1727912373018
   PubMedGoogle Scholar
• BarryMFlynnDMLetskyEARisdonRALong-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progressBr Med J19742590916204821036
   PubMed Web of Science ®Google Scholar
• BrittenhamGMGriffithPMNienhuisAWEfficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia majorN Engl J Med199433195675738047080
   PubMed Web of Science ®Google Scholar
• Bronspiegel-WeintrobNOlivieriNFTylerBAndrewsDFFreedmanMHHollandFJEffect of age at the start of iron chelation therapy on gonadal function in β-thalassemia majorN Engl J Med1990323117137192388669
   PubMed Web of Science ®Google Scholar
• OlivieriNFNathanDGMcMillanJHSurvival in medically treated patient with homozygous β-thalassemiaN Engl J Med199433195745788047081
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCRugolottoSDe StefanoPSurvival and complications in patients with thalassemia major treated with transfusion and deferoxamineHaemotologica2004891011871193
   PubMed Web of Science ®Google Scholar
• De VirgiliisSCossuPSannaGIron chelation in transfusion-dependent thalassemia with chronic hepatitisActa Haematol198267149566800202
   PubMed Web of Science ®Google Scholar
• SmithRSIron excretion in thalassaemia major after administration of chelating agentsBr Med J1962253191577158013989576
   PubMed Web of Science ®Google Scholar
• SchaferAIRabinoweSLe BoffMSBridgesKCheronRGDluhyRLong-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overloadArch Intern Med19851457121712213925909
   PubMedGoogle Scholar
• DavisBAPorterJBLong-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemiaBlood20009541229123610666195
   PubMed Web of Science ®Google Scholar
• DeleaTEEdelsbergJSofryginOConsequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature reviewTransfusion200747101919192917880620
   PubMed Web of Science ®Google Scholar
• De VirgillisSCongiaMFrauFDeferoxamine-induced growth retardation in patients with thalassemia majorJ Pediatr198811346616693171791
   PubMed Web of Science ®Google Scholar
• RachmilewitzEAGiardinaPJHow I treat thalassemiaBlood2011118133479348821813448
   PubMed Web of Science ®Google Scholar
• CunninghamMJMacklinEANeufieldEJCohnARThalassemia Clinical Research Network. Complications of beta-thalassemia major in North AmericaBlood20041041343914988152
   PubMed Web of Science ®Google Scholar
• PorterJBJaswonMSHuehnsEREastCAHazellJWDesferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosageBr J Haematol19897334034092605127
   PubMed Web of Science ®Google Scholar
• OlivieriNFBuncicJRChewEVisual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusionsN Engl J Med1986314148698733485251
   PubMed Web of Science ®Google Scholar
• YacobovichJStarkPBarzilai-BirenbaumSAcquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasiroxJ Pediatr Hematol Oncol201032756456720733517
   PubMed Web of Science ®Google Scholar
• PigaARoggeroSSalussoliaIMassanoDSerraMLongoFDeferiproneAnn N Y Acad Sci20101202757820712776
   PubMed Web of Science ®Google Scholar
• CappelliniMDMusallamKMTaherATOverview of iron chelation therapy with desferrioxamine and deferiproneHemoglobin200933Suppl 1S58S6920001633
   PubMedGoogle Scholar
• Borgna-PignattiCCappelliniMDDe StefanoPCardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia majorBlood200610793733373716373663
   PubMed Web of Science ®Google Scholar
• MamtaniMKulkarniHInfluence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysisBr J Haematol2008141688289018355381
   PubMed Web of Science ®Google Scholar
• AndersonLJWestwoodMAHoldenSMyocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBr J Haematol2004127334835515491298
   PubMed Web of Science ®Google Scholar
• HoffbrandAVCohenAHershkoCRole of deferiprone in chelation therapy for transfusional iron overloadBlood20031021172412637334
   PubMed Web of Science ®Google Scholar
• CohenARGalanelloRPigaADipalmaAVulloCTrictaFSafety profile of the oral iron chelator deferiprone: a multicentre studyBr J Haematol2000108230531210691860
   PubMed Web of Science ®Google Scholar
• OlivieriNFBrittenhamGMMcLarenCELong-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia majorN Engl J Med199833974174239700174
   PubMed Web of Science ®Google Scholar
• PippardMJWeatherallDJOral iron chelation therapy for thalassaemia: an uncertain sceneBr J Haematol200011112511091177
   PubMed Web of Science ®Google Scholar
• TannerMAGalanelloRDessiCA randomized, placebo- controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonanceCirculation2007115141876188417372174
   PubMed Web of Science ®Google Scholar
• FisherSABrunskillSJDoreeCChowdhuryOGoodingSRobertsDJOral deferiprone for iron chelation in people with thalassaemiaCochrane Database Syst Rev20138CD00483923966105
   PubMed Web of Science ®Google Scholar
• CappelliniMDCohenAPigaAA Phase 3 study of deferasirox (ICL670), a once daily iron chelator, in patients with beta-thalassemiaBlood200510793455346216352812
   PubMed Web of Science ®Google Scholar
• PennellDJPorterJBPigaAA 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)Blood2014123101447145424385534
   PubMed Web of Science ®Google Scholar
• GlicksteinHElRBShvartsmanMCabantchikZIIntracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cellsBlood200510693242325016020512
   PubMed Web of Science ®Google Scholar
• Borgna-PignattiCCappelliniMDDe StefanoPCardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorBlood200610793733373716373663
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet]Exjade (deferasirox): Boxed Warning. FDA Safety Alerts for Human Medical Products2010 Available from: http://www.fda.gov/Safety/Med-Watch/%20SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm200850.htmAccessed June 28, 2016
   Google Scholar
• WonkeBWrightCHoffbrandAVCombined therapy with deferiprone and desferrioxamineBr J Haematol199810323613649827905
   PubMed Web of Science ®Google Scholar
• De DomenicoIWardDMKaplanJSpecific iron chelators determine the route of ferritin degradationBlood2009114204546455119671920
   PubMed Web of Science ®Google Scholar
• HoffbrandAVTaherACappelliniMDHow I treat transfusional iron overloadBlood2012120183657366922919029
   PubMed Web of Science ®Google Scholar
• OlivieriNFBerrimanAMTylerBJDavisSAFrancombeWHLiuPPContinuous intravenous administration of deferoxamine in adults with severe iron overloadAm J Hematol199241161631503101
   PubMed Web of Science ®Google Scholar
• LadisVChouliarasGBerdousiHKanavakisEKattamisCLongitudinal study of survival and causes of death in patients with thalassemia major in GreeceAnn N Y Acad Sci2005105444545016339695
   PubMed Web of Science ®Google Scholar
• RoudbariMSoltani-RadMRoudbariSThe survival analysis of beta thalassemia major patients in South East of IranSaudi Med J20082971031103518626536
   PubMed Web of Science ®Google Scholar
• EhlersKHGiardinaPJLesserMLEngleMAHilgartnerMWProlonged survival in patients with beta-thalassemia major treated with deferoxamineJ Pediatr19911184 Pt 15405452007928
   PubMed Web of Science ®Google Scholar
• FosburgMNathanDGTreatment of Cooley’s anemiaBlood19907634354442198956
   PubMed Web of Science ®Google Scholar
• LoukopoulosDVoskaridouEStamoulakatouAHydroxyurea therapy in thalassemiaAnn N Y Acad Sci19988501201289668534
   PubMed Web of Science ®Google Scholar
• ItaliaKYJijinaFFMerchantREffect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic studyJ Clin Pathol201063214715020154037
   PubMed Web of Science ®Google Scholar